- Conditions
- Multiple Sclerosis
- Interventions
- Cladribine, Placebo, Rebif® new formulation (RNF)
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 617 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–8
of 8
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome (CIS)
- Interventions
- Prebiotics (Prebiotin Prebiotic Fiber Stick Pac), Probiotics (Visbiome®)
- Dietary Supplement
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- New York, New York • Pittsburgh, Pennsylvania
- Conditions
- Multiple Sclerosis
- Interventions
- Teriflunomide, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 618 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 19
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Fort Collins, Colorado + 15 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Tovaxin Autologous T cell vaccine, Placebo
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 33
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 29 more
- Conditions
- Optic Neuritis
- Interventions
- Atacicept, Placebo matched to atacicept
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome
- Interventions
- Not listed
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 10 Years to 45 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Sclerosis, Clinically Isolated Syndrome
- Interventions
- Ocrelizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 6
- States / cities
- San Francisco, California • Aurora, Colorado • Chicago, Illinois + 3 more
- Conditions
- Multiple Sclerosis
- Interventions
- Atorvastatin, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more